New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both ...

From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss.

Boehringer Ingelheim & LEO Pharma partner to commercialize and further develop Spevigo: Ingelheim, Germany Wednesday, July 16, 2025, 15:00 Hrs [IST] Boehringer Ingelheim, a biopha ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company recently updated its ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...